Of the roughly 1.2 million Americans living with type 1 diabetes, 64% carry overweight or obesity — a number that makes the therapeutic gap between glucose control and weight management acutely real. Phase 2 data presented at the 2026 ADA Scientific Sessions for acmopatide (CT-868), a once-daily dual GLP-1/GIP receptor agonist, suggest that gap can be narrowed with a single agent, without adding insulin.
The randomized, placebo-controlled trial enrolled 111 adults with type 1 diabetes and a BMI of at least 27 kg/m², assigning them to one of three acmopatide doses or placebo over 16 weeks. At the 4.1 mg dose — the middle of three tested — A1C dropped 0.34 percentage points from a baseline of 7.5%, and 56% of participants reached the recommended A1C target below 7%. Across doses, the drug produced up to 7% weight loss and trimmed insulin requirements by up to 15%, both dose-dependent effects. The tolerability profile raised no new flags. Those are meaningful absolute numbers for a 16-week study in a population where the insulin-weight gain cycle is a well-documented clinical trap.
The design question worth pressing is what 16 weeks actually proves. A1C reflects roughly three months of glycemic exposure, so the trial’s primary endpoint window barely clears one full measurement cycle. Durability beyond that, and the trajectory of insulin dose reduction over a longer treatment course, remain uncharacterized. Context also matters: tirzepatide has been evaluated in a small phase 2 trial in type 1 diabetes, and semaglutide showed meaningful glycemic and weight benefits in the ADJUST-T1D trial in type 1 patients on automated insulin delivery systems — so incretin biology in this population is being interrogated from multiple angles simultaneously. No GLP-1/GIP dual agonist carries FDA approval specifically for type 1 diabetes, and approved insulin-sparing options in the space, such as Lantidra and teplizumab, operate through entirely different mechanisms targeting disease progression rather than metabolic burden.
The single number to watch as acmopatide advances is sustained insulin dose reduction in a trial long enough to capture hypoglycemia risk at steady state. If adjunct incretin therapy meaningfully lowers basal insulin requirements without increasing hypoglycemic episodes over 52 weeks, the regulatory and clinical calculus for this class in type 1 diabetes changes substantially.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
